Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma

摘要: Clinical trials of agents targeting the vascular endothelial growth factor A (VEGF-A) pathway in gastric adenocarcinoma (GA) suggest that these therapies may have varying efficacy different races. VEGF-A serum and/or VEGF receptor 2 (VEGFR-2) CD31-positive tumor vessels (VEGFR-2/CD31) were measured 118 Caucasians and 263 Asians who underwent resection at two institutions correlated with overall survival (OS). Blood was drawn before any treatment. Patients receiving neoadjuvant treatment excluded from VEGFR-2 analysis. Compared Asians, older (mean age 66–73 vs 59–62 years), had more proximal tumors, advanced TNM stage. In cohort, a median level 95 % higher than much standard deviation (88 ± 6.206 45 ± 76 pg/ml, p < 0.001). The 5-year OS for patients low versus high levels 72 43 % (p = 0.001) 86 77 % (p = 0.236). worse VEGFR-2/CD31 (49 73 %, p = 0.038), while there no significant difference (80 90 %, p = 0.119). On multivariate analyses prognostic factors (excluding margin status), independent predictors only Caucasians. resectable GA, are but not suggesting importance this GA progression among